ZHAO Pin ,BIAN Lei ,YANG Yue. FDA's Risk Evaluation and Mitigation Strategy and the Inspirations to Our Country[J]. Chinese Journal of Pharmacovigilance, 2013, 10(3): 140-134.
[1] Institute of Medicine.THE FUTURE OF DRUG SAFETY:ACTIONSTEPSFORCONGRESS[EB/OL]. 2006-09.http://www.iom.edu/~/media/Files/Report%20Files/2006/The-Future-of-Drug-Safety/futureofdrugsafety_reportbrief.pdf. [2] Beckloff Associates, Inc..Risk Evaluation and Mitigation Strategies(REMS) Under FDAAA[EB/OL].2009-10-05. http://www.cardinalhealth.com/beckloff/documents/pdf/REMS-white-paper_final%20100509_website.pdf. [3] FDA.Food and Drug Administration Amendments of 2007[EB/OL].2007-09-27. http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. [4] FDA.Federal Register[EB/OL].2008-03-27.http://www.fda.gov/OHRMS/DOCKETS/98fr/E8-6201.pdf. [5] FDA. Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies [EB/OL].2011-11. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM244570.pdf. [6] FDA.FDA introduces new safety measures for extended-release and long-acting opioid medications [EB/OL].2012-07-09.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm. [7] ASHP.Experts SayREMSAssessmentsNeedWork[EB/OL]. 2012-07-15.http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=3739.
